Percheron Sets Closing Date for Entitlement Offer to Fund Therapeutic Pipeline

Percheron Therapeutics ( (AU:PER) ) has shared an announcement.

Percheron Therapeutics has reminded shareholders that its non-renounceable pro-rata entitlement offer of fully paid ordinary shares is scheduled to close at 5 p.m. AEST on 8 April 2026. Eligible shareholders in Australia, New Zealand, Singapore, Hong Kong and the U.K. can subscribe for two new shares for every five held at $0.005 per share, with one free unlisted option for every two shares subscribed, and can also seek additional securities through a shortfall offer at the directors’ discretion.

Any new shares and options not taken up under the entitlement offer will be made available to eligible shareholders and other investors via the shortfall offer on the same terms, subject to potential scale-back. The capital raising is intended to support Percheron’s ongoing development activities, including advancing its lead VISTA-targeting antibody program, and may strengthen the company’s funding position as it moves toward further clinical trials and seeks to enhance its competitive standing in oncology and rare disease therapeutics.

The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.

More about Percheron Therapeutics

Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercialising novel therapies for oncology and rare diseases. Its lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator VISTA, which has completed a phase I trial in advanced cancer patients and is expected to enter further clinical trials in 2026.

Technical Sentiment Signal: Sell

Current Market Cap: A$9.13M

Learn more about PER stock on TipRanks’ Stock Analysis page.